Trial record 3 of 73 for:    graft leipzig

Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02669680
Recruitment Status : Recruiting
First Posted : February 1, 2016
Last Update Posted : October 15, 2018
Information provided by (Responsible Party):
Thomas Berg, University of Leipzig

Brief Summary:
Multicentre, open, randomised, and controlled trial conducted in patients diagnosed with acute on chronic liver failure (ACLF) who meet inclusion/exclusion criteria.The objective of GRAFT-trial is to evaluate efficacy and safety of subcutaneously administered granulocyte colony-stimulating factor (G-CSF) in patients with ACLF. All patients will receive standard medical care for ACLF according to the guidelines. Patients in the experimental arm additional receive subcutaneous injections of G-CSF.

Condition or disease Intervention/treatment Phase
Acute-On-Chronic Liver Failure Drug: G-CSF Other: Standard therapy Not Applicable

Detailed Description:
The acute on chronic liver failure (ACLF) is characterised by a severe deterioration of liver function due to a precipitating event on top of an underlying chronic liver disease. As therapeutic options are limited the mortality rate lies between 40 and 80% at 3 months. The granulocyte colony-stimulating factor (G-CSF) mobilized stem- as well as immune cells and improved liver function in preclinical trials. G-CSF treatment reduced the rate of infectious complications and significantly improved patients´ survival in acute on chronic liver failure, shown recently in small randomised studies. Thus, G-CSF is a promising treatment option that needs to be evaluated in a multi-centre controlled trial. The GRAFT trial will randomise patients with ACLF between standard of care with and without G-CSF. All participants will be followed for 12 months in order to evaluate safety and efficacy of G-CSF. If successful, the GRAFT trial has the potential to change clinical practice in acute on chronic liver failure.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 292 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure: A Multicentre Randomized Trial
Study Start Date : February 2016
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: G-CSF + Standard therapy
Standard care of acute-on-chronic liver failure and application of G-CSF
Drug: G-CSF
G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
Other Name: Filgrastim

Other: Standard therapy
Active Comparator: Standard therapy
Standard care of acute-on-chronic liver failure
Other: Standard therapy

Primary Outcome Measures :
  1. Transplant-free survival up to 90 days (death or transplant count as events) [ Time Frame: 90 days ]

Secondary Outcome Measures :
  1. Overall survival time until the end of follow-up [ Time Frame: 360 days ]
  2. Transplant-free survival time until the end of follow-up [ Time Frame: 360 days ]
  3. Complications of ACLF (hepatorenal syndrome (HRS), variceal bleeding, ascites, hepatic encephalopathy (HE)) [ Time Frame: 90 days/360 days ]
  4. Infections (proven infection necessitating systemic use of antibiotics) [ Time Frame: 90 days/360 days ]
  5. Liver function - assessed by MELD-Score - during the course of treatment and follow-up [ Time Frame: 360 days ]
  6. Liver function - assessed by Child-Pugh-Score - during the course of treatment and follow-up [ Time Frame: 360 days ]
  7. Duration of the initial hospital stay [ Time Frame: up to 360 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Acute-on-chronic liver failure (ACLF) according to the consensus criteria recently defined by the CANONIC study group [Moreau 2013]. Patients with acute decompensation of cirrhosis [defined as acute development of one or more of the following: ascites (onset and/or worsening), hepatic encephalopathy (onset and/or worsening), gastrointestinal haemorrhage, bacterial infection] are classified as ACLF if one of the following applies:

    • single kidney failure (serum creatinine level ≥ 2 mg/dl) or
    • single failure of one of the following organ systems: liver, coagulation, circulation, or respiration, together with a serum creatinine level ranging from 1.5 to < 2.0 mg/dl and/or mild to moderate hepatic encephalopathy or
    • single cerebral failure together with serum creatinine level ranging from 1.5 to < 2.0 mg/dl or
    • two or more organ failures. Organ failures are defined according to the CLIF-C OFs [Jalan 2014].
  2. Age ≥ 18 years, male or female
  3. Written informed consent from patient, legal or authorized representative or a confirmation of justification of trial participation by an independent medical consultant PLEASE NOTE: In case of confirmation by the independent medical consultant a deferred informed consent from patient, legal or authorized representative has to be given

Exclusion Criteria:

  1. Prior not curatively treated or active malignancies
  2. Sickle cell disease
  3. septic shock, defined by the following symptom complex: bacteraemia AND SIRS AND shock
  4. WBC-count of > 50 x 109/L
  5. Known HIV infection
  6. Known intolerance to filgrastim
  7. Suspected lack of compliance
  8. Pregnant or nursing women
  9. Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial (participants using a hormone-based method have to be informed of possible effects from the trial medication on contraception).
  10. Participation in other interventional trials

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02669680

Contact: Cornelius Engelmann, MD 0049 34197 ext 12330
Contact: Anett Schmiedeknecht, PhD 0049 34197 ext 16256

University Hospital of Leipzig Recruiting
Leipzig, Sachsen, Germany, 04103
Contact: Adam Herber, MD         
Universitätsklinikum Aachen Recruiting
Aachen, Germany
Contact: Christian Trautwein, Prof.         
Charité-Campus Virchow-Klinikum Recruiting
Berlin, Germany
Contact: Tobias Müller, MD         
Universitätsklinikum Bonn Recruiting
Bonn, Germany
Contact: Christian Strassburg, Prof.         
Universitätsklinikum Düsseldorf Recruiting
Düsseldorf, Germany
Contact: Dieter Häussinger, Prof.         
Universitätsklinikum Essen Recruiting
Essen, Germany
Contact: Christian Lange, Prof.         
Klinikum der J.W. Goethe- Universität Recruiting
Frankfurt, Germany
Contact: Stefan Zeuzem, Prof.         
Universitätsklinik Freiburg Active, not recruiting
Freiburg, Germany
Universitätsklinikum Halle (Saale) Recruiting
Halle, Germany
Contact: Alexander Zipprich, MD         
Medizinische Hochschule Hannover Recruiting
Hannover, Germany
Contact: Peter Manns, Prof.         
Universitätsklinikum Heidelberg Recruiting
Heidelberg, Germany
Contact: Jan Pfeiffenberger, MD         
Universitätsklinikum des Saarlandes Recruiting
Homburg, Germany
Contact: Frank Lammert, Prof.         
Universitätsklinikum Jena Recruiting
Jena, Germany
Contact: Andreas Stallmach, Prof.         
Universitätsklinikum Schleswig-Holstein Active, not recruiting
Kiel, Germany
Universitätsklinikum KÖLN Recruiting
Köln, Germany
Contact: Tobias Goeser, Prof.         
HELIOS Park-Klinikum Leipzig Not yet recruiting
Leipzig, Germany
Contact: Markus Zachäus, MD         
Klinikum St. Georg gGmbH Recruiting
Leipzig, Germany
Contact: Ingolf Schiefke, Prof.         
Universitätsklinikum Magdeburg AöR Recruiting
Magdeburg, Germany
Contact: Ali Canbay, Prof.         
Universitätsmedizin Mainz Recruiting
Mainz, Germany
Contact: Peter Galle, Prof.         
Universitätsklinikum Tübingen Recruiting
Tübingen, Germany
Contact: Christoph Berg, MD         
St. Josefs-Hospital Recruiting
Wiesbaden, Germany
Contact: Christoph Sarrazin, Prof.         
Sponsors and Collaborators
University of Leipzig
Study Director: Thomas Berg, Prof. University Hospital of Leipzig;

Responsible Party: Thomas Berg, Prof. Dr. med., University of Leipzig Identifier: NCT02669680     History of Changes
Other Study ID Numbers: GRAFT
First Posted: February 1, 2016    Key Record Dates
Last Update Posted: October 15, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Liver Failure
Hepatic Insufficiency
End Stage Liver Disease
Acute-On-Chronic Liver Failure
Liver Diseases
Digestive System Diseases
Liver Failure, Acute
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs